GlaxoSmithKline reinforced its commitment to responsible management of ethical, social and environmental concerns and, in particular, to play a leading role in supporting healthcare in the developing world. The publication of GSK's "Corporate Responsibility Report 2003 - Making a difference every day" confirms progress in the diverse and extensive contribution the company is making to meet the needs of society across the globe.

Commenting on the publication of the report, JP Garnier, CEO said, "Corporate responsibility has particular resonance for the pharmaceutical sector. Our business is creating medicines and vaccines to treat and prevent disease - something that society needs and values. This report deals with important issues for our business and explains how we are addressing them. I am particularly proud of our global community investment which, through a variety of programmes targeting health and education, is assisting under-served communities in over 100 countries".

As per the community investment highlights from the year, the overall investment in global community activities valued at £338 million, equivalent to 5.3 per cent of pre-tax profit. This compares with a global investment of £239 million in 2002, equivalent to 4.3 per cent of pre-tax profit, which was the largest amount donated to global good causes by any FTSE-100 company.

The £338 million investment includes donations of GSK medicines for international healthcare support efforts valued at £116 million, £97 million cash contributions for community programmes and initiatives, plus GSK medicines valued at £125 million donated for low income patients in the USA. Medicines valued at £116 million donated for international healthcare support efforts.